Indeed, homozygous loss of human FXR function causes severe progressive familial intrahepatic cholestasis (46), and activation of FXR by OCA treatment protects against hepatic inflammation and fibrosis in rodent models of cholestasis, cirrhosis, and NASH (3, 4, 18). The gene discussed is NR1H4; the disease is familial intrahepatic cholestasis.